Evotec and Novartis collaboration

Published: 15-Jun-2002


Hamburg-based Evotec OAI is intensifying its collaboration with long-term partner Novartis, which is to acquire additional EVOscreen screening devices beyond the scope agreed in the original contract.

The EVOscreen Mark II system delivered to Novartis in summer 2000 has proven itself as a successful screening platform in Novartis's internal operations, as a result of which the company has commissioned Evotec to upgrade the current Mark II system in Basel to increase its throughput even further.

In addition, Novartis has decided to implement the next generation Mark III system of the EVOscreen technology, and has ordered additional benchtop devices to secure a corresponding capacity increase in assay development.

Evotec's proprietary technologies allow the throughput of Mark III to be well above 100,000 tests per day. The integration of a special cell dispensing unit and a combined fluorescence and chemiluminescence detection system makes the system also suited for the performance of cellular assays, the company says.

You may also like